Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China

INTRODUCTION: To compare the cost-effectiveness of vedolizumab with that of conventional therapy in patients with moderate-to-severe active Crohn’s disease (CD) in China. METHODS: A decision tree and Markov model were built to predict the lifetime cost and health outcomes in the induction phase and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ting, Sheng, Yanan, Guan, Haijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342392/
https://www.ncbi.nlm.nih.gov/pubmed/34089502
http://dx.doi.org/10.1007/s12325-021-01806-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342392/
https://www.ncbi.nlm.nih.gov/pubmed/34089502
http://dx.doi.org/10.1007/s12325-021-01806-7

Ejemplares similares